Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Impact of pharmacists' interventions and simvastatin dose restrictions.

Shoulders BR, Franks AS, Barlow PB, Williams JD, Farland MZ.

Ann Pharmacother. 2014 Jan;48(1):54-61. doi: 10.1177/1060028013511323. Epub 2013 Nov 6.

PMID:
24259645
2.

Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.

Alford JC, Saseen JJ, Allen RR, Nair KV.

Pharmacotherapy. 2012 Jul;32(7):623-30. doi: 10.1002/j.1875-9114.2011.01090.x. Epub 2012 May 8.

PMID:
22570173
3.

Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database.

Tuchscherer RM, Nair K, Ghushchyan V, Saseen JJ.

Am J Cardiovasc Drugs. 2015 Feb;15(1):27-34. doi: 10.1007/s40256-014-0096-x.

PMID:
25348907
4.
5.

Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial.

Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB; Ezetimibe Study Group.

Mayo Clin Proc. 2004 May;79(5):620-9.

PMID:
15132403
6.

Begin with the real-world patients of non-goal-achieved hypercholesterolemia in taiwan through the ezetimibe/simvastatin tablet - The BRAVO Study.

Huang JC, Lee TY, Liou MJ, Lin CM, Pei D, Chen ZC, Liu RT, Kwok CF.

Curr Med Res Opin. 2011 Aug;27(8):1645-51. doi: 10.1185/03007995.2011.594425. Epub 2011 Jun 23.

PMID:
21699369
7.

Team-based approach to addressing simvastatin safety concerns.

Robinson M, Gunning K, Pippitt K, McAdam-Marx C, Jennings BT.

J Am Pharm Assoc (2003). 2013 Sep-Oct;53(5):539-44. doi: 10.1331/JAPhA.2013.13019.

PMID:
24030132
8.

Clinical and economic outcomes in patients switched to simvastatin in a community-based family medicine practice.

Willey VJ, Reinhold JA, Willey KH, Kelly BL, Cziraky MJ.

Int J Clin Pract. 2010 Aug;64(9):1235-8. doi: 10.1111/j.1742-1241.2010.02423.x.

PMID:
20653799
9.

A cluster randomised controlled trial of a pharmacist-led collaborative intervention to improve statin prescribing and attainment of cholesterol targets in primary care.

Lowrie R, Lloyd SM, McConnachie A, Morrison J.

PLoS One. 2014 Nov 18;9(11):e113370. doi: 10.1371/journal.pone.0113370. eCollection 2014.

10.
11.

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW; STELLAR Study Group.

Am J Cardiol. 2003 Jul 15;92(2):152-60.

PMID:
12860216
12.

Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.

McCormack T, Harvey P, Gaunt R, Allgar V, Chipperfield R, Robinson P; IN-PRACTICE study.

Int J Clin Pract. 2010 Jul;64(8):1052-61. doi: 10.1111/j.1742-1241.2010.02429.x. Epub 2010 May 12.

PMID:
20487050
13.

An evaluation of low-dose simvastatin in achieving LDL goal: a retrospective chart review.

Schnee DM, Bogdanski L, Zaiken K, McCloskey WW.

Manag Care Interface. 2007 May;20(5):53-7.

PMID:
17626594
14.

Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.

Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW; Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.

Clin Ther. 2004 Sep;26(9):1388-99. Erratum in: Clin Ther. 2005 Jan;27(1):142.

PMID:
15531001
15.
16.

Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns.

Nkansah N, Mostovetsky O, Yu C, Chheng T, Beney J, Bond CM, Bero L.

Cochrane Database Syst Rev. 2010 Jul 7;(7):CD000336. doi: 10.1002/14651858.CD000336.pub2. Review.

PMID:
20614422
17.

Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.

Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, Tershakovec AM.

Curr Med Res Opin. 2006 Oct;22(10):2041-53.

PMID:
17022864
18.

Lipid management and cholesterol goal attainment in Norway.

Ose L, Skjeldestad FE, Bakken IJ, Levorsen A, Alemao EA, Yin DD, Borgström F, Jönsson L.

Am J Cardiovasc Drugs. 2006;6(2):121-8.

PMID:
16555865
19.

Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.

Costa-Scharplatz M, Ramanathan K, Frial T, Beamer B, Gandhi S.

Clin Ther. 2008 Jul;30(7):1345-57.

PMID:
18691996
20.

A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.

Illingworth DR, Crouse JR 3rd, Hunninghake DB, Davidson MH, Escobar ID, Stalenhoef AF, Paragh G, Ma PT, Liu M, Melino MR, O'Grady L, Mercuri M, Mitchel YB; Simvastatin Atorvastatin HDL Study Group.

Curr Med Res Opin. 2001;17(1):43-50.

PMID:
11464446

Supplemental Content

Support Center